Our approach
Patients lead. Mechanism decides.
Four principles govern how a QR Genetics program starts, what advances, and what we are willing to claim.
Pillar 01
Patients lead the discovery
We begin with human disease, not an abstract target or a computational prediction.
- Discovery begins with real patients and their genetic mutations.
- Human disease biology informs target and indication selection.
- Rare genetic diseases provide high-resolution insight into causal mechanisms.
- Patient evidence is incorporated throughout discovery and validation.
Pillar 02
Mechanism guides the medicine
We identify what drives the disease before determining which medicine can change it.
- Genetics establishes the starting point.
- Mechanistic biology explains what has gone wrong.
- AI connects disease mechanisms with potential therapeutic interventions.
- Drug selection is based on biological fit, not correlation alone.
Pillar 03
Existing drugs accelerate the path
We unlock new precision uses for medicines that already exist.
- Focus on existing drugs with known clinical histories.
- Potential to reduce early development risk, cost and time.
- New indications can create differentiated, protectable assets.
- Offers pharma a path to recover value from shelved, deprioritised, failed or maturing molecules.
Pillar 04
Clinical evidence closes the loop
Our predictions are tested where they matter most, in humans.
- Patients have already been treated based on QR Genetics’ insights.
- Human outcomes inform and strengthen the platform.
- A clinical program is advancing with Yale.
- A continuous learning loop runs between patients, biology, prediction and clinical evidence.
Rare to common
From rare genetic insight to broader disease impact.
A highly penetrant mutation can reveal a disease mechanism that is also relevant to much larger patient populations. Once that mechanism and the therapeutic response are validated, we evaluate expansion into related, more prevalent diseases.
01Rare patient
02Causal mechanism
03Existing drug
04Clinical validation
05Broader indication